{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:58:52Z","timestamp":1789397932744,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012276","name":"Tillotts Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.cgh.2023.02.014","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T11:40:11Z","timestamp":1677498011000},"page":"243-251.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome"],"prefix":"10.1016","volume":"22","author":[{"given":"Vivek C.","family":"Goodoory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok K.","family":"Tuteja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-4359","authenticated-orcid":false,"given":"Alexander C.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.02.014_bib1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","article-title":"Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis","volume":"5","author":"Oka","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.014_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.014_bib3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(20)31548-8","article-title":"Irritable bowel syndrome","volume":"396","author":"Ford","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.02.014_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41575-020-0286-8","article-title":"Global burden of irritable bowel syndrome: trends, predictions and risk factors","volume":"17","author":"Black","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.014_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/apt.16939","article-title":"Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom","volume":"56","author":"Goodoory","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.014_bib6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41395-018-0262-x","article-title":"Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem","volume":"113","author":"Frandemark","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/apt.17132","article-title":"Impact of Rome IV irritable bowel syndrome on work and activities of daily living","volume":"56","author":"Goodoory","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.014_bib8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/00365520310004524","article-title":"Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life","volume":"38","author":"Pace","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.014_bib10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1177\/2050640618779923","article-title":"Post-infectious IBS: defining its clinical features and prognosis using an internet-based survey","volume":"6","author":"Card","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2023.02.014_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/gut.47.6.804","article-title":"Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome","volume":"47","author":"Spiller","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.014_bib12","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1572-0241.2003.07542.x","article-title":"Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome","volume":"98","author":"Dunlop","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/gut.2003.021154","article-title":"Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis","volume":"53","author":"Wang","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.014_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00535-011-0379-9","article-title":"Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review","volume":"46","author":"Ford","year":"2011","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/ajg.2009.700","article-title":"Increased proteasome-mediated degradation of occludin in irritable bowel syndrome","volume":"105","author":"Coeffier","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib16","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/gast.2002.33579","article-title":"Activation of the mucosal immune system in irritable bowel syndrome","volume":"122","author":"Chadwick","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.014_bib17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/ajg.2008.94","article-title":"Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms","volume":"104","author":"Cremon","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.gastro.2003.11.055","article-title":"Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome","volume":"126","author":"Barbara","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.014_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2006.11.039","article-title":"Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome","volume":"132","author":"Barbara","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.014_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2036.2003.01640.x","article-title":"Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome","volume":"18","author":"Dunlop","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.014_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib22","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/ecco-jcc\/jjab010","article-title":"Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis","volume":"15","author":"Barberio","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.02.014_bib23","doi-asserted-by":"crossref","first-page":"S711","DOI":"10.14309\/00000434-201210001-01749","article-title":"Mesalamine granules 1500 mg once daily for 12 weeks provides adequate relief of IBS symptoms in irritable bowel syndrome with diarrhea: results from a phase 2 trial","volume":"107","author":"Aron","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gutjnl-2015-309122","article-title":"A\u00a0mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)","volume":"65","author":"Lam","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.014_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gutjnl-2014-308188","article-title":"Randomised controlled trial of mesalazine in IBS","volume":"65","author":"Barbara","year":"2016","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2023.02.014_bib26","doi-asserted-by":"crossref","first-page":"S896","DOI":"10.1016\/S0016-5085(20)32926-7","article-title":"The effect of long-acting mesalamine of post-infectious irritable bowel syndrome","volume":"158","author":"Tuteja","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.014_bib27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3109\/00365521.2012.694903","article-title":"Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome: a pilot study","volume":"47","author":"Tuteja","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib28","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/apt.17182","article-title":"Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity","volume":"56","author":"Castro Tejera","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.014_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.schres.2013.10.029","article-title":"Imputation of response rates from means and standard deviations in schizophrenia","volume":"151","author":"Samara","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.cgh.2023.02.014_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.cgh.2023.02.014_bib31","author":"Higgins"},{"key":"10.1016\/j.cgh.2023.02.014_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cgh.2023.02.014_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.cgh.2023.02.014_bib34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2023.02.014_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2023.02.014_bib36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2023.02.014_bib37","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2023.02.014_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2036.2009.04041.x","article-title":"Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study","volume":"30","author":"Corinaldesi","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.014_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15171\/mejdd.2016.47","article-title":"Mesalazine has no effect on mucosal immune biomarkers in patients with diarrhea-dominant irritable bowel syndrome referred to Shariati Hospital: a randomized double-blind, placebo-controlled trial","volume":"9","author":"Ghadir","year":"2017","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.cgh.2023.02.014_bib40","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1053\/j.gastro.2018.08.042","article-title":"BUG-1\/LMC Study Group. Efficacy and safety of budesonide, vs mesalazine or placebo, as induction therapy for lymphocytic colitis","volume":"155","author":"Miehlke","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.014_bib41","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.014_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG Clinical Guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib43","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.014_bib44","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/gutjnl-2018-318160","article-title":"Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis","volume":"69","author":"Black","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.014_bib45","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","article-title":"Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-surveillance marketing data","volume":"101","author":"Chang","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib46","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/apt.14504","article-title":"Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder","volume":"47","author":"Harinstein","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.014_bib47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2036.2009.04041.x","article-title":"Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study","volume":"30","author":"Corinaldesi","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.014_bib48","doi-asserted-by":"crossref","first-page":"S711","DOI":"10.14309\/00000434-201210001-01749","article-title":"Mesalamine granules 1500 mg once daily for 12 weeks provides adequate relief of IBS symptoms in irritable bowel syndrome with diarrhea: results from a phase 2 trial","volume":"107","author":"Aron","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib49","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3109\/00365521.2012.694903","article-title":"Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome: a pilot study","volume":"47","author":"Tuteja","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.014_bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gutjnl-2014-308188","article-title":"Randomised controlled trial of mesalazine in IBS","volume":"65","author":"Barbara","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.014_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gutjnl-2015-309122","article-title":"A\u00a0mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)","volume":"65","author":"Lam","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.014_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15171\/mejdd.2016.47","article-title":"Mesalazine has no effect on mucosal immune biomarkers in patients with diarrhea-dominant irritable bowel syndrome referred to Shariati Hospital: a randomized double-blind, placebo-controlled trial","volume":"9","author":"Ghadir","year":"2017","journal-title":"Middle East J Dig Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2023.02.014_bib53","doi-asserted-by":"crossref","first-page":"S896","DOI":"10.1016\/S0016-5085(20)32926-7","article-title":"The effect of long-acting mesalamine of post-infectious irritable bowel syndrome","volume":"158","author":"Tuteja","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.014_bib54","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/apt.17182","article-title":"Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity","volume":"56","author":"Castro Tejera","year":"2022","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523001568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523001568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:45:56Z","timestamp":1761543956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523001568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1542356523001568"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.02.014","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}